- Home
- GENC vs IMAB Comparison
GENC vs IMAB Comparison
Compare GENC & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENC
- IMAB
- Stock Information
- Founded
- GENC 1894
- IMAB 2014
- Country
- GENC United States
- IMAB United States
- Employees
- GENC N/A
- IMAB N/A
- Industry
- GENC Construction/Ag Equipment/Trucks
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- GENC Industrials
- IMAB Health Care
- Exchange
- GENC Nasdaq
- IMAB Nasdaq
- Market Cap
- GENC 215.0M
- IMAB 200.9M
- IPO Year
- GENC N/A
- IMAB 2020
- Fundamental
- Price
- GENC $14.85
- IMAB $2.13
- Analyst Decision
- GENC
- IMAB Strong Buy
- Analyst Count
- GENC 0
- IMAB 3
- Target Price
- GENC N/A
- IMAB $6.33
- AVG Volume (30 Days)
- GENC 27.7K
- IMAB 603.0K
- Earning Date
- GENC 08-08-2025
- IMAB 05-15-2025
- Dividend Yield
- GENC N/A
- IMAB N/A
- EPS Growth
- GENC N/A
- IMAB N/A
- EPS
- GENC 0.99
- IMAB N/A
- Revenue
- GENC $113,166,000.00
- IMAB N/A
- Revenue This Year
- GENC N/A
- IMAB N/A
- Revenue Next Year
- GENC N/A
- IMAB N/A
- P/E Ratio
- GENC $15.34
- IMAB N/A
- Revenue Growth
- GENC 7.70
- IMAB N/A
- 52 Week Low
- GENC $10.80
- IMAB $0.60
- 52 Week High
- GENC $24.88
- IMAB $3.08
- Technical
- Relative Strength Index (RSI)
- GENC 58.08
- IMAB 50.03
- Support Level
- GENC $14.72
- IMAB $2.05
- Resistance Level
- GENC $15.47
- IMAB $2.41
- Average True Range (ATR)
- GENC 0.66
- IMAB 0.34
- MACD
- GENC 0.02
- IMAB -0.08
- Stochastic Oscillator
- GENC 85.03
- IMAB 13.68
About GENC Gencor Industries Inc.
Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).